Chronic Kidney Disease/Bone and Mineral Metabolism: The Imperfect Storm

Seminars in Nephrology

Volumn 29, Issue 2, 2009, Pages 97-104

  Williams, Mark E ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

hyperparathyroidism; Kidney; mineral; vitamin D

Indexed keywords

CALCIUM; CINACALCET; FIBROBLAST GROWTH FACTOR 23; PLACEBO;

ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DENSITY; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY FUNCTION; METABOLIC BONE DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; SECONDARY HYPERPARATHYROIDISM;

BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MINERALS; PARATHYROID HORMONE; RISK FACTORS;

EID: 64049087494     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2009.01.002     Document Type: Article

References (59)

1. Almaden Y., Hernandez A., Torregrosa V., Canckejo A., Sabate L., Fernandez Cruz L., et al. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 9 (1998) 1845-1852
2. Levin A., Bakris G.L., Molitch M., Sulders M., Tian J., Williams L.A., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71 (2007) 31-38
3. Block G.A., Klasssen P.S., and Lazarus J.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 (2004) 2208-2218
4. Kovesdy C.P., Ahmadzadeh S., Anderson J.E., and Kalantar-Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 73 (2008) 1296-1302
5. Nickolas T.L., Leonard M.B., and Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int 74 (2008) 721-731
6. Hamdy N.A., Kanis J.A., and Benetn M.N. Effect of alfacalcidiol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310 (1995) 358-363
7. Bouillon R., Bischoff-Ferrari H., and Willett W. Vitamin D and health: from mice and man. J Bone Miner Res 23 (2008) 974-979
8. Pasch A. Bone mass gain after parathyroidectomy. Kidney Int 74 (2008) 697-702
9. Andress D.L. Adynamic bone in patients with chronic kidney disease. Kidney Int 73 (2008) 1345-1354
10. Brandenburg V.M., and Floege J. Adynamic bone disease-bone and beyond. Nephrol Dial Transplant Plus 3 (2008) 135-147
11. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (2003) S1-S201
12. Go A.S., Chertow G.M., Fan D., McCulloch D.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1302
13. Hruska K.A., Mathew S., Lund R., Qiu P., and Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int 74 (2008) 148-157
14. Block G.A., Temple E., and Hulbert-Shearon T.E. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31 (1998) 607-614
15. Kestenbaum B., Sampson J.N., and Rudser K.D. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16 (2005) 52-58
16. Voormolen N. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 27 (2007) 2909-2916
17. Goodman W.G., Goldin J., and Juison B.D. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 (2000) 1478-1483
18. Dhingra R., Sullivan L.M., Fox C.S., Wang T.J., D'Agostino R.B., Gaziano M., et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 167 (2007) 879-885
19. Schwarz S., Rivedi B.K., Kalantar-Zadeh K., and Kovesdy C.P. Association of disorders of mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 1 (2006) 825-831
20. Ketteler M., Rix M., Fan S., Pritchard N., Oestergard O., Chasan-Taber S., et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 3 (2008) 1125-1150
21. Salusky I.B. A new era in phosphate binder therapy: what are the options?. Kidney Int 70 (2006) S10-S16
22. Liu S., and Quarles L.D. How fibroblast growth factor 23 works. J Am Soc Nephrol 18 (2007) 1637-1641
23. Razzaque M.S., and Lanske B. The emerging role of the fibroblast growth factor -23-Klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 194 (2007) 1-10
24. Emmett M. What does serum fibroblast growth factor 23 do in hemodialysis patients?. Kidney Int 73 (2008) 3-8
25. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 (2006) 770
26. Ferrari S.L., Bonjour J.P., and Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90 (2005) 1519-1524
27. Burnett S.M., Gunawardene S.C., Bringhurst F.R., Juppner H., Lee H., and Finkelstein J.S. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21 (2006) 1187
28. Shigematsu T., Kazama J.J., Yamashita T., Fukumoto S., Hosoya T., Gejyo F., et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44 (2004) 250-256
29. Larsson T., Nisbeth U., Ljunggren O., Juppner H., and Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64 (2003) 2272-2279
30. Isakova T., Gutierrez O., Shah A., Castaldo L., Holmes J., Lee H., et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 19 (2008) 615-623
31. Fliser D., Kollerits B., Neyer U., Ankerst D.P., Lhotta K., Lingenhel A., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) study. J Am Soc Nephrol 18 (2007) 2600-2607
32. Guetierez O., Isakova T., Rhee E., Shah A., and Holmes J. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16 (2005) 2205-2215
33. Collins M.T., Lindsay J.R., Jain A., Kelly M.H., Cutler C.M., Weinstein L.S., et al. Fibroblast growth factor-23 is regulated by 1alpha, 25-dihrydoxyvitamin D. J Bone Miner Res 20 (2005) 1944-1950
34. Urena-Torres P., Friedlander G., and deVernejoul M.C. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int 73 (2008) 102-109
35. Parfitt A.M. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 52 (1997) 3-6
36. Felsenfeld A.J., Rodriguez M., and Aguilera-Tejero A. Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism. Clin J Am Soc Nephrol 2 (2007) 1283-1287
37. Dusso A.S., Pavlopoulos T., Naumovich L., Lu Y., Finch J., Brown A.J., et al. p21 (WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int 59 (2001) 855-861
38. Cozzolino M., Lu Y., Finch J., Slatopolsky E., and Dusso A.S. p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 60 (2001) 2109-2117
39. Arcidiacono M.V., Sato T., Alvarez-Hernandez D., Yang J., Tokumoto M., Gonzalez-Suarez I., et al. EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. J Am Soc Nephrol 19 (2008) 310-320
40. Dusso A.S., Sato T., Arcidiacono M.V., Alvarez-Hernandez D., Yang J., Gonzalez-Suarez I., et al. Pathogenic mechanisms for parathyroid hyperplasia. Kidney Int Suppl 102 (2006) S8-S11
41. Arcidiacono MV, Cozzolino M, Spiegel N, Tokumoto M, Yang J, Lu Y, et al. Activator protein 2(alpha) mediates parathyroid TGF-{alpha} self-induction in secondary hyperparathyroidism. J Am Soc Nephrol. 2008 [accessed 2008 October 15]. Epub PMID 18579641.
42. Schoppet M., Shroff R.C., Hofbauer L.C., and Shanahan C.M. Exploring the biology of vascular calcification in chronic kidney disease: what's circulating?. Kidney Int 73 (2008) 384-390
43. Ix J.H., Katz R., Kestenbaum B., Fried L.F., Kramer H., and Stehman-Breen C. Association of mild to moderate kidney dysfunction and coronary calcification. J Am Soc Nephrol 19 (2008) 579-585
44. El-Abbadi M., and Giachelli C.M. Mechanisms of vascular calcification. Adv Chronic Kidney Dis 14 (2007) 54-66
45. Luo G., Ducy P., and McKee M.D. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386 (1997) 78-81
46. Ketteler M., and Giachelli C. Novel insights into vascular calcification. Kidney Int 70 (2006) S5
47. Andress D.L. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 69 (2006) 33
48. Mizobuchi M., Finch J.L., Martin D., and Slatopolsky E. Differential effects of vitamin D receptor activators in vascular calcification in uremic rats. Kidney Int 72 (2007) 9-16
49. Al-Aly Z. Metabolic acidosis and vascular calcification: using blueprints from bone to map a new venue for vascular research. Kidney Int 73 (2008) 37-44
50. Mendoza F.J., Lopez L., and Montes de Oca P. Metabolic acidosis inhibits soft tissue calcification in uremic rats. Kidney Int 3 (2008) 407-414
51. Harrington P.E., and Fotsch C. Calcium sensing receptor activators: calcimimetics. Curr Med Chem 14 (2007) 3027-3034
52. Moe S.M. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67 (2005) 760-771
53. deFrancisco A.L., Izquierdo M., Cunningham J., Pinera C., Palomar R., Fresnedo G.F., et al. Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet. Nephrol Dial Transplant 23 (2008) 2895-2901
54. Valle C, Rodriquez M, Santamaria R, Almaden Y, Rodriguez ME, Canadillas S, et al. Cinacalcet reduces the set point of the PTH-calcium curve. J Am Soc Nephrol. 2008 [accessed 2008 October 17]. Epub PMID 18632847.
55. Coyne D.W. Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Nat Clin Pract 4 (2008) 364-367
56. deFrancisco A.L.M., Pinera C., and Palomar R. Cinacalcet should be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Nat Clin Pract 4 (2008) 366-369
57. Charytan C. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 46 (2005) 58-66
58. Health Canada online. Sensipar R no longer indicated for chronic kidney disease patients (stages 3 and 4) not receiving dialysis. [accessed 2008 September 9]. Available from: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2007/sensipar_hpc-cps_e.html.
59. Chonchoi M., Locatelli F., Abboud H.E., Charytan C., de Francicso A.L., Jolly S., et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis 53 (2009) 197-207